Arresting tumor cell proliferation and inhibition of AKT pathway via the use of multikinase inhibitor sorafenib forthe treatment of glioblastoma

Abstract

Glioblastoma multiforme is one of the common forms of brain cancer found worldwide, and treatment options are limited for this deadly disease. Various targeted treatments are being investigated, but no breakthroughs have yet been made. One of the most promising aspects of the glioblastoma treatment is the restriction of the intracellular signal transduction,also known asthe strain transformingpathway, and recently it has become the hotspot of brain cancer research. Sorafenib is a model drug that has shown signs of success in preclinical trials. Sorafenib, which is a multi-kinase inhibitor, induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 and thus poses a promising aspect in developing a potential treatment of glioblastoma. This thesis report focuses on the use of sorafenib for the Protein kinase B (AKT) inhibition as a potential cure for glioblastoma.